Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04590235
Other study ID # D1346C00011
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date December 16, 2020
Est. completion date August 31, 2026

Study information

Verified date May 2024
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Chinese Paediatric and Adult Subjects with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN).


Description:

Paediatric and adult patients with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) will be evaluated in the screening visit to confirm eligibility. Approximately 16 paediatric and 16 adult qualified patients will receive oral selumetinib 25 mg/m^2 twice a day (approximately every 12 hours) continuously until disease progression or unacceptable drug-related toxicity, whichever occurs first. Once a patient has discontinued the study treatment then the patient will be followed for specified period for safety assessment


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 32
Est. completion date August 31, 2026
Est. primary completion date August 16, 2022
Accepts healthy volunteers No
Gender All
Age group 3 Years to 99 Years
Eligibility Inclusion Criteria: - Paediatric cohort: Chinese subjects =3 years and <18 years of age - Adult cohort: Chinese subjects =18 years of age at the time of study enrollment - Subjects must be diagnosed with (i) NF1 as per NIH Consensus Development Conference Statement and(ii) PN is defined as a neurofibroma that has grown along the length of a nerve and may involve multiple fascicles and branches. (iii) inoperable PN - Subjects must have at least one measurable typical or nodular PN - Absolute neutrophil count =1.5×10^9/L, haemoglobin =9g/dL, and platelet count =100×10^9/L. Subject must be without growth factor support and platelet transfusion support 7 days before the screening assessment. - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2×upper limit of normal (ULN), total bilirubin =1.5×ULN except in the case of subjects with documented Gilbert's disease (=2.5×ULN). Exclusion Criteria: - Evidence of malignant peripheral nerve sheath tumour. - Clinically significant cardiovascular disease - Prior malignancy (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject had been disease free for =2 years or which would not have limited survival to <2 years) or other cancer requiring treatment with chemotherapy or radiation therapy. - Subjects with the following ophthalmological findings/conditions: Current or past history of retinal pigment epithelial detachment/central serous retinopathy or retinal vein occlusion; Intraocular pressure >21 mmHg (or ULN adjusted by age) or uncontrolled glaucoma (irrespective of IOP); Subjects with known glaucoma and increased IOP who do not have meaningful vision (light perception only or no light perception) and are not experiencing pain related to the glaucoma, may be eligible after discussion with the study physician; Any other significant abnormality on ophthalmic examination that would make the subject unsuitable for enrolment into the study, as assessed by the investigator.

Study Design


Intervention

Drug:
Selumetinib
All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m^2. After a washout period of 2 days, oral selumetinib 25 mg/m^2 twice daily will be administered continuously. Subjects will continue to receive selumetinib until disease progression or unacceptable drug-related toxicity, whichever occurs first. 10 mg and 25 mg capsules strengths available.

Locations

Country Name City State
China Research Site Shanghai
China Research Site Shanghai

Sponsors (2)

Lead Sponsor Collaborator
AstraZeneca Merck Sharp & Dohme LLC

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events Occurrence/frequency.
Relationship to IP as assessed by investigator.
Common Terminology Criteria for Adverse Events (CTCAE) grade.
Seriousness.
Death.
Adverse events leading to discontinuation of IP.
Adverse events of special interest.
For paediatric cohort: from signing the informed consent form until up to 3 years after last subject dosed; For adult cohort: from signing the informed consent form until up to 2 years+30 days after last subject dosed.
Primary Area under the concentration-time curve from zero to the last measurable concentration (AUC0-t) of selumetinib and its metabolite (N-desmethyl selumetinib) in Chinese paediatric and adult subjects with NF 1 and inoperable Plexiform Neurofibromas AUC0-t after single dose and multiple doses administration From the first consent patient first dose to last patient steady state PK collection. Expected duration is approximately 1 year.
Primary Maximum plasma concentration (Cmax) of selumetinib and its metabolite (N-desmethyl selumetinib) in Chinese paediatric and adult subjects with NF 1 and inoperable Plexiform Neurofibromas Cmax after single dose and multiple doses administration From the first consent patient first dose to last patient steady state PK collection. Expected duration is approximately 1 year.
Primary Terminal half-life (t1/2) of selumetinib and its metabolite (N-desmethyl selumetinib) in Chinese paediatric and adult subjects with NF 1 and inoperable Plexiform Neurofibromas t1/2 after single dose and multiple doses administration From the first consent patient first dose to last patient steady state PK collection. Expected duration is approximately 1 year.
Secondary objective response rate (ORR) of selumetinib in Chinese paediatric and adult subjects with Neurofibromatosis Type 1 and inoperable Plexiform Neurofibromas measured by 3D volumetric magnetic resonance imaging (MRI) of the target and nontarget PN First patient first dose until up to 2 years after last subject dosed
Secondary duration of response (DoR) of selumetinib in Chinese paediatric and adult subjects with Neurofibromatosis Type 1 and inoperable Plexiform Neurofibromas measured by 3D volumetric magnetic resonance imaging (MRI) of the target and nontarget PN First patient first dose until up to 2 years after last subject dosed
Secondary progression-free survival (PFS) of selumetinib in Chinese paediatric and adult subjects with Neurofibromatosis Type 1 and inoperable Plexiform Neurofibromas measured by 3D volumetric magnetic resonance imaging (MRI) of the target and nontarget PN First patient first dose until up to 2 years after last subject dosed
Secondary time to progression (TTP) of selumetinib in Chinese paediatric and adult subjects with Neurofibromatosis Type 1 and inoperable Plexiform Neurofibromas measured by 3D volumetric magnetic resonance imaging (MRI) of the target and nontarget PN First patient first dose until up to 2 years after last subject dosed
Secondary time to response (TTR) of selumetinib in Chinese paediatric and adult subjects with Neurofibromatosis Type 1 and inoperable Plexiform Neurofibromas measured by 3D volumetric magnetic resonance imaging (MRI) of the target and nontarget PN First patient first dose until up to 2 years after last subject dosed
Secondary Measures of Physical function via Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire First patient first dose until up to 2 years after last subject dosed
Secondary Measures health-related quality of life (HRQoL) via PedsQL (paediatric cohort, self-and parent-reported) First patient first dose until up to 2 years after last subject dosed
Secondary Measures of pain via FLACC scale First patient first dose until up to 2 years after last subject dosed
Secondary Measures health-related quality of life (HRQoL) via EORTC QLQ-C30 (adult cohort) First patient first dose until up to 2 years after last subject dosed
Secondary Measures health-related quality of life (HRQoL) via PlexiQoL (adult cohort) First patient first dose until up to 2 years after last subject dosed
Secondary Measures of pain via Faces Pain Scale (revised) First patient first dose until up to 2 years after last subject dosed
Secondary Measures of pain via NRS-11 First patient first dose until up to 2 years after last subject dosed
Secondary Measures of pain via PII First patient first dose until up to 2 years after last subject dosed
Secondary Measures of pain via Pain Medication Survey First patient first dose until up to 2 years after last subject dosed
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01362803 - AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Phase 1/Phase 2
Completed NCT00352599 - Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) Phase 1
Completed NCT05005845 - NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Phase 2
Completed NCT03531814 - Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials N/A
Completed NCT00846430 - Medical Treatment of "High-Risk" Neurofibromas Phase 2
Completed NCT03433183 - SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Phase 2
Recruiting NCT05331105 - HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Phase 2
Completed NCT03310996 - Non-invasive Stimulation in Neurofibromatosis Type 1 N/A
Recruiting NCT03406208 - Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing N/A
Recruiting NCT04750928 - Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas Phase 1/Phase 2
Not yet recruiting NCT06262113 - A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1 N/A
Active, not recruiting NCT04924608 - Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Phase 3
Recruiting NCT02544022 - Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
Recruiting NCT04941027 - Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
Completed NCT02153931 - Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
Completed NCT05196854 - Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1 N/A
Active, not recruiting NCT01650142 - Modifying Genes in Neurofibromatosis 1 N/A
Completed NCT05377008 - Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1 N/A
Completed NCT04879160 - Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
Recruiting NCT05735717 - MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Phase 2